A number of 13-alkoxy milbemycin derivatives were synthesized to evaluate their anthelmintic activity. We report the strategy for developing a potent anthelmintic product, 13-[4-(N-methanesulfonyl-N-methylamino)-phenylethyloxy]milbemycin.
The details of the structure-activity relationships of those derivatives are also discussed.
Milbemycin derivatives are known as potent antiparasitic agents and have attracted a great deal of interest recently1).
On the other hand, ivermectin, which is widely used as a potent parasiticide for livestock2), is known to possess similar activity to milbemycins against endoparasites. The structures of the milbemycin derivatives and ivermectin closely resemble each other, having a 16-membered ring ( Fig. 1) , although ivermectin has higher activity than milbemycins.
This difference in the activity is due to the substituent at the 25-position. It is known that the lipophilicity on the substituent at the 25-position contributes to their anthelmintic activity (Table 1) . Thus it seemed easier to synthesize the ivermectin derivatives than milbemycin derivatives to find more active products. However, owing to availability of substrates, we decided to develop new milbemycin derivatives, which have as strong activity as ivermectin.
As it is also known that the substituent at the 13-position strongly influences the activity3), a great number of substituents at the 13-position, which overcome the disadvantage of the substituent at the 25-position, have been examined. Evaluations of 13-halomilbemycin4,5), 13-alkylmilbemycin6,7), and 13-acyloxymilbemycin8,9) have already been reported. According to those studies, the 13-acyloxymilbemycins have quite strong activity and are thus very attractive, but the ester bond seems to be susceptible to esterase in vivo, producing the inactive 13-hydroxymilbemycin. That is why we aimed our research at 13-alkoxymilbemycins, which have an ether bond in place of the susceptible ester bond at the 13-position. The 13-alkoxymilbemycins also turned out to have strong anthelmintic activity, as reported in our previous We report the strategy for developing the series of derivatives to find an efficient and effective product and also describe the details of their structure-activity relationships.
Chemistry
Using our method already reported in previous papers10,11) a number of derivatives was synthesized from milbemycin A4 via 13-iodomilbemycin (2)10) or 15-hydroxy-5-oxomilbemycin (3)11) (Scheme 1).
Biological Results and Discussion
The activity of this series of 13-alkoxymilbemycin derivatives was evaluated by oral administration to rats infected with Nippostrongylus brasiliensis by use of the method described in the previous paper.
Firstly, the length of the carbon chain between the benzene ring and the oxygen atom (Fig. 2 , position A) was examined (Table 2) . Those results showed that the efficacy was the strongest when the number of the carbon chain was two (4, 5, 6). The efficacy clearly decreased when the chain was shorter or longer. In addition, this tendency was not dependent on the substituent at the benzene ring. Thus, the length of the carbon chain was fixed as two.
Secondly, substitution on the carbon chain was examined (Table 3) . When the polar substituent was on the carbon chain, the efficacy decreased (7, 8) . When the chain had a ring formation (9, 10), the efficacy did not change much compared to the straight chain. Regarding its availability and its facility in synthesis, the straight chain was chosen as a candidate.
Thirdly, the position of the substituent on the benzene ring ( Fig. 2 , position B) was examined (Table 4 ). The activity of the derivatives was maximized when the substituent on the benzene ring was at the p-position (4, 11). An amino (or substituted amino) group was chosen as a candidate to provide a greater number of potential derivatives for pursuing an ideal compound, although there did not seems to much difference in activity between the Lastly, the various N-substituted aminophenylethyloxy derivatives were examined (Fig. 2 , position C) ( Table 5) .
From the evaluation, N-methanesulfonyl-N methylaminophenylethyloxymilbemycin (1) turned out to possess considerably high and efficient activity. 
4-(N-Methanesulfonyl-N-methylamino)phenethyl
Alcohol (1) (1) 4-Aminophenylethyloxy-t-butyldimethylsilane 4-Nitrophenethyl alcohol (10.02g, 60mmol) was dissolved in DMF (70ml), imidazole (5.44g, 80mmol) and t-butyldimethylsilyl chloride (12.08g, 80mmol) were added and the mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with EtOAc (500ml) and washed with H2O twice, dried over anhydrous Na2SO4, and evaporated in vacuo. The residue was dissolved in 90% AcOH (300ml), then the solution was was stirred at room temperature for 20 minutes, and then the mixture was diluted with EtOAc (700ml) and filtered.
The filtrate was washed with H2O twice, dried over anhydrous Na2SO4, and evaporated in vacuo. The residue was chromatographed on silica gel with the eluent (EtOAc:cyclohexane=1:3) to obtain 4-aminophenylethyloxy-t-butyl dimethyl silane (12.55g, 83.2% yield).
(2) 4-(N-Methansulfonyl-N-methylamino)phenethyl Alcohol 4-Aminophenylethyloxy t-butyldimethyl silane was dissolved in 1,2-dichloroethane (20ml), pyridine (2.0ml) and methanesulfonyl chloride (1.63ml, 21mmol) were added. The mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with EtOAc, then washed with 1N-HCl, H2O, 4% NaHCO3, and H2O again, dried over anhydrous Na2SO4 and evaporated in vacuo. The residue was dissolved in N-methylpyrolidone (100ml), iodomethane (1.56ml, 25mmol) and sodium hydride (55%, 873mg, 20mmol) were added, and the mixture was stirred at room temperature for 3 hours. The reaction mixture was poured into cold diluted HCl, extracted with EtOAc, and washed with H2O, dried over anhydrous Na2SO4, and evaporated in vacuo. The residue was dissolved in MeOH (50ml), p-toluenesulfonic acid monohydrate (50mg) was added and the mixture was stirred at room temperature for 20 minutes. The reaction mixture was diluted with EtOAc (200ml), washed with 4% NaHCO3 and H2O, dried over anhydrous Na2SO4, then evaporated in vacuo. The residue was crystallized from EtOAc and hexane to obtain 2-[4-(N-methansulfonyl-N-methylamino)phenyl]ethanol (1.61g, 58.8% yield).
copper(I) iodide (480mg, 2.52mmol), trifluoromethanesulfonic acid (0.35ml, 4.0mmol) and 15-hydroxy-5-oxomilbemycin (1.36g, 2.5mmol)11) were added, and the mixture was stirred at room temperature for 25 minutes. The reaction mixture was diluted with EtOAc and filtered. The filtrate was washed with H2O twice, 4% NaHCO3, and H2O again, dried over anhydrous Na2SO4, then evaporated in vacuo. To remove the remaining 4-(N-methansulfonyl-N-methylamino)phenethyl alcohol as a crystal, the residue was crystallized from EtOAc and cyclohexane and filtered. Then the filtrate was chromatographed on silica gel with the eluent to retrieve additional 1 (0.887g) from the filtrate. Thus, the total amount of 1 was 9.09g (84.0% yield).
13-(4-Aminophenylethyloxy)-5-hydroxymilbemycin (4) ( 1) 
13-{5-[(N-Methylcarbamoyl)-amino]indan-2-yloxy}-5-
hydroxymilbemycin (9) and (10) (1) 13-(5-Nitro-2-indanyloxy)-5-oxomilbemycin 13-Iodomilbemycin (620mg, 0.93mmol) was dissolved in 1,2-dichloroethane (10ml), 5-nitro-indan-2-ol (895mg, 5.0mmol) and mercury(II) iodide (650mg, 1.43mmol) mixture was diluted with EtOAc and filtered. The filtrate was washed with 20% potassium iodide twice, 10% NaHCO3, 0.5N-HCl, H2O, 4% NaHCO3 and H2O again, dried over anhydrous Na2SO4, then evaporated in vacuo.
The residue was chromatographed on silica gel with the eluent (EtOAc:cyclohexane=1:3) to obtain 13-(5-nitro-2-indanyloxy) 5-oxomilbemycin (350mg, 52.5% yield). Derivative 11 was prepared from 4 in a similar manner as that described for the preparation of 9-(3).
13-(4-Aminobenzyloxy)-5-hydroxymilbemycin (12) (1) 13-(4-Nitrobenzyloxy)-5-oxomilbemycin 4-Nitrobenzyl alcohol (2.30g, 15.0mmol), mercury (II) iodide (2.06g, 4.53mmol) and 2,6-lutidine (0.36ml, 3.09mmol) were added to a solution of 13-iodomilbemycin (2.0g, 3.0mmol)10) in 1,2-dichloroethane (10ml). The mixture was stirred at room temperature for 90 minutes. The derivative 17 was prepared from 13 in a similar manner as that described for the preparation of 6.
13-(2-Phenylethyloxy)-5-hydroxymilbemycin (18)
Derivative 18 was prepared from 13-iodomilbemycin and phenethyl alcohol in a similar manner as that described for the preparation of 5: MS m/z=662 (M+); 1H NMR (CDCl3) 
13-[2-(4-Methoxyacetylaminophenyl)ethyloxy]-5-hydroxymilbemycin (28)
Derivative 28 was prepared from 4 and methoxyacetyl chloride in a similar manner as that described for the 
